Most people who end up adopting an American Eskimo puppy are absolutely thrilled with their decision, but the ones who regret it - or worse, the ones who ultimately give up the dog - do so because they didn’t realize what they were getting into ahead of time. They need plenty of exercise and training, and if you’re not willing or able to supply both, you could have quite the terror on your hands.
#Eximo gamers full#
That’s not to say that these dogs aren’t well-behaved - far from it, in fact.īut they are full of intelligence and energy, and if not properly harnessed, those traits can quickly cause a dog to become a handful. If you bring home an American Eskimo, you’ll soon find out just how wrong that assumption can be. After all, how much trouble could a 25-pound pup be?
In addition to developing devices for other vascular indications, Eximo Medical said it is working on an add-on diagnostic tool and a device for gastrointestinal procedures.įDA recently released draft guidance for companies making 510(k) submissions for peripheral vascular atherectomy devices covering the four main categories of the devices: directional, rotational, orbital and laser.Many people operate under the assumption that a smaller dog will be less work than their more sizable counterparts. "The study results up to six months have been very impressive despite treating diverse lesions such as calcium, thrombus, and restenosis including ISR, both above and below the knee," John Rundback, primary investigator and director of the interventional institute at Holy Name Medical Center in Teaneck, N.J., said in a press release. Safety and efficacy primary endpoints were met with high margins in the pivotal study, the company said. The device was evaluated in a single-arm, multi-center, open-label, non-randomized pilot study of 50 patients in Europe, and in a pivotal, single-arm, multi-center, open-label, non-randomized investigational device exemption study in 97 subjects in the United States and Europe.
The company said the 355 nm wavelength provides advantages over traditional 308 nm lasers in safety, effectiveness and ease of use. The Eximo Medical B-Laser uses optical fibers that deliver short pulses in a catheter-based procedure to dissolve the lesion inside an artery before balloon angioplasty or stent placement. More than 200 million people worldwide are estimated to have the disease, including 8 million in the United States, according to the American College of Cardiology. The condition, which is most common in the legs, is characterized by narrowing of the blood vessels primarily due to the buildup of fatty plaque. The market for treatments to address PAD continues to attract new entrants as the global prevalence of the disease increases. Eximo said it intends to leverage the technology to develop additional devices for other vascular indications, including lead extraction, coronary artery disease, thrombectomy and venous disease.The system was approved for the treatment of infrainguinal stenoses and occlusion, including in-stent restenosis (ISR). The device is the first 355 nm laser system cleared in the United States for PAD and is designed to address unmet clinical needs for multiple vascular conditions, the company said.Eximo Medical, a small Israel-based medical device maker, on Monday announced it received FDA 510(k) clearance for its B-Laser single-use atherectomy system for treating peripheral artery disease (PAD).
0 kommentar(er)
